# Cooley

## William DuVal

**Special Counsel** 



wduval@cooley.com

+1 703 456 8663

Reston

Emerging Companies Mergers and Acquisitions Venture Capital Capital Markets

William primarily represents high-growth companies in the life sciences, digital health and tech sectors, along with leading venture capital firms in their investment activities in the same sectors. His practice focuses on public and private offerings, venture capital transactions, strategic partnerships and collaborations, M&A, and corporate governance.

William received his JD and MBA from the University of Virginia, where he was president of the JD/MBA Society. He received his BS from the University of Virginia McIntire School of Commerce, with concentrations in finance and marketing.

#### Representative company-side and underwriter-side public offerings:

- Aclaris Therapeutics \$92.9 million follow-on offering
- Epizyme \$75 million follow-on offering
- argenx \$862.5 million follow-on offering
- Autolus Therapeutics \$150 million initial public offering (IPO)
- Helius Medical Technologies \$16 million follow-on offering
- Biohaven Pharmaceutical Holding \$193.6 million IPO

### Education

University of Virginia School of Law JD, 2016

University of Virginia Darden School of Business MBA, 2016

University of Virginia McIntire School of Commerce BS, 2008

#### Admissions & Credentials

Virginia